Cor Vasa 2025, 67(Suppl.2):14-17 | DOI: 10.33678/cor.2025.049

(Beta-blockers in the secondary prevention of myocardial infarction with respect to recent results of ABYSS and REDUCE-AMI trials)

Petr Janský
Kardiochirurgická klinika, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice v Motole, Praha, Česká republika

Beta-blockers the prognosis patients myocardial Their is in who signs cardiac or ventricular However, to European the positive also in patients. of that shown a in and have conducted patients major attacks at time diagnosis modern and acute long were available. new trials needed investigate the benefits in with left systolic who being with pharmacotherapy. The contradictory results of the recently published REDUCE-AMI and ABYSS studies do not cur- rently warrant a change in the recommendations for secondary prevention of myocardial infarction.

Keywords: Beta-blockers, Myocardial infarction, Secondary prevention

Received: March 16, 2025; Revised: March 16, 2025; Accepted: March 20, 2025; Prepublished online: June 2, 2012; Published: April 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janský P. (Beta-blockers in the secondary prevention of myocardial infarction with respect to recent results of ABYSS and REDUCE-AMI trials). Cor Vasa. 2025;67(Suppl.2):14-17. doi: 10.33678/cor.2025.049.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807. Go to original source... Go to PubMed...
    2. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-1714.
    3. Hjalmarson A, Herlitz J, Holmberg S, et al. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67:I26-I32.
    4. Olsson G, Rehnqvist N, Sjögren A, et al. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985;5:1428-1437. Go to original source... Go to PubMed...
    5. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992;13:28-32. Go to original source... Go to PubMed...
    6. Freemantle N, Cleland J, Young P, et al. Betablockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-1737. Go to original source... Go to PubMed...
    7. Jánosi A, Ghali JK, Herlitz J, et al. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J 2003;146:721-728. Go to original source... Go to PubMed...
    8. Jneid H, Addison D, Bhatt DL, et al. 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST- -Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circ Cardiovasc Qual Outcomes 2017;10:e000032. Go to original source... Go to PubMed...
    9. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014;127:939-953. Go to original source... Go to PubMed...
    10. Raposeiras-Roubín S, Abu-Assi E, Redondo-Diéguez A, et al. Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant Today? Rev Esp Cardiol (Engl Ed) 2015;68:585-591. Go to original source...
    11. Neumann A, Maura G, Weill A, et al. Clinical Events After Discontinuation of β-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases. Circ Cardiovasc Qual Outcomes 2018;11:e004356. Go to original source... Go to PubMed...
    12. Huang BT, Huang FY, Zuo ZL, et al. Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. Am J Cardiol 2015;115:1529-1538. Go to original source... Go to PubMed...
    13. Dahl Aarvik M, Sandven I, Dondo TB, et al. Effect of oral β-blocker treatment on mortality in contemporary post- -myocardial infarction patients: a systematic review and meta- -analysis. Eur Heart J Cardiovasc Pharmacother 2019;5:12-20. Go to original source... Go to PubMed...
    14. Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med 2024;390:1372-1381. Go to original source... Go to PubMed...
    15. Silvain J, Cayla G, Ferrari E, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med 2024;391:1277-1286. Go to original source... Go to PubMed...
    16. Munkhaugen J, Ruddox V, Halvorsen S, et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J 2019;208:37-46. Go to original source... Go to PubMed...
    17. Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials 2020;21:415. Go to original source... Go to PubMed...
    18. Rossello X, Raposeiras-Roubin S, Latini R, et al. Rationale and design of the pragmatic clinical trial tREatment with Beta- -blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother 2022;8:291-301. Go to original source... Go to PubMed...
    19. Choi KH, Kim J, Kang D, et al. Discontinuation of β-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial. BMJ Open 2024;14:e086971. Go to original source... Go to PubMed...
    20. Steg PG. Routine Beta-Blockers in Secondary Prevention - On Injured Reserve. N Engl J Med 2024;390:1434-1436. Go to original source... Go to PubMed...
    21. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-177. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes